Given its role in various diseases, PDGFR is a target for therapeutic interventions. Inhibitors of PDGFR, such as imatinib, are used in cancer treatment to block the aberrant signaling pathways. These therapies have shown efficacy in treating malignancies that exhibit PDGFR mutations or overexpression.
